Published in Infect Drug Resist on January 11, 2012
Invasive fungal infections in transplant recipients. Ther Adv Infect Dis (2013) 0.85
In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates. J Med Microbiol (2014) 0.77
In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother (2015) 0.77
Invasive Fungal Sinusitis Involving the Orbital Apex in a Patient with Chronic Renal Failure. Neuroophthalmology (2015) 0.75
Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. Int J Clin Oncol (2012) 0.75
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med (2002) 7.85
Echinocandin antifungal drugs. Lancet (2003) 5.92
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol (2004) 4.03
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect (2002) 3.63
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell (2005) 3.44
Emerging opportunistic yeast infections. Lancet Infect Dis (2011) 3.27
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother (2006) 3.25
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 2.74
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis (2000) 2.63
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med (2004) 2.30
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2007) 2.29
Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis (1998) 2.12
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother (1997) 2.02
Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol (1999) 2.02
Echinocandin antifungal drugs in fungal infections: a comparison. Drugs (2011) 1.67
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs (2009) 1.59
Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother (2004) 1.58
Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol (2008) 1.52
Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother (2002) 1.50
Shifting patterns in the epidemiology of nosocomial Candida infections. Chest (2003) 1.46
Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol (2010) 1.35
Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol (2003) 1.31
Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. J Clin Microbiol (1998) 1.28
Aspergillus ustus infections among transplant recipients. Emerg Infect Dis (2006) 1.21
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis (2003) 1.21
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother (2010) 1.18
Echinocandins: the newest class of antifungals. Ann Pharmacother (2009) 1.14
Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis (2003) 1.10
Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis (1991) 1.09
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther (2010) 1.04
Emerging moulds: epidemiological trends and antifungal resistance. Mycoses (2011) 0.98
Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol (2008) 0.95
Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore) (2010) 0.92
Invasive mold infections: recent advances in management approaches. Leuk Lymphoma (2009) 0.92
Current options in antifungal pharmacotherapy. Pharmacotherapy (2008) 0.90
Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica (2004) 0.88
Emerging fungal diseases: the importance of the host. Clin Lab Med (2004) 0.86
Emerging fungal resistance. Clin Lab Med (2004) 0.85
An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol (2006) 0.81
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy (2007) 2.10
A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2002) 1.77
Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant (2010) 1.08
Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther (2010) 1.04
Polymicrobial candidemia. Diagn Microbiol Infect Dis (2002) 1.00
Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR. J Clin Microbiol (2010) 0.93
Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation (2008) 0.93
Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant (2007) 0.88
Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis (2010) 0.85
Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant (2005) 0.85
Appropriate use of polymerase chain reaction for detection of herpes simplex virus 2 in cerebrospinal fluid of patients at an inner-city hospital. Diagn Microbiol Infect Dis (2006) 0.83
West Nile virus encephalitis: an emerging disease in renal transplant recipients. Clin Transplant (2004) 0.83
Safety of posaconazole. Expert Opin Drug Saf (2013) 0.77
Failure to obtain microbiological culture and its consequence in a mesh-related infection. BMJ Case Rep (2013) 0.75
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother (2016) 0.75
Voriconazole toxicity masquerading as septic shock. Leuk Lymphoma (2015) 0.75
Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation. Clin Transplant (2013) 0.75
Catheter-related bloodstream infection due to Mycobacterium neoaurum in a patient with acute leukemia. Leuk Lymphoma (2014) 0.75